Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celebrex Label Adds Cardiovascular Risk Language

This article was originally published in The Pink Sheet Daily

Executive Summary

Celecoxib labeling revision includes long-term safety data from three celecoxib trials, one of which suggests increased cardiovascular risk. Celebrex also gains ankylosing spondylitis indication.

You may also be interested in...



Celebrex Polyp Trial Meta-Analysis Finds CV Risk In Line With Previous Findings

Analysis of cardiovascular risk in the APC and PreSAP trials is consistent with current labeling warnings, firm asserts.

Celebrex Polyp Trial Meta-Analysis Finds CV Risk In Line With Previous Findings

Analysis of cardiovascular risk in the APC and PreSAP trials is consistent with current labeling warnings, firm asserts.

NSAID Safety Data Merit No Further Action, EMEA Committee Says

However, the Committee for Medicinal Products for Human Use recommends consistent labeling at the national level.

Related Content

Topics

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel